Rochester, Minn.-based Mayo Clinic has developed a minimally invasive procedure that, when combined with endoscopic sleeve gastroplasty, may approach the weight loss of surgical sleeve gastrectomy.
Gastric fundal mucosal ablation targets ghrelin production in the stomach’s fundus, a hormonal driver of hunger not addressed by ESG. Combined, the procedures led to 23.5% total body weight loss in early trials, compared to 7.7% with GFMA alone. Sleeve gastrectomy averages 29% at 24 months, according to a March 10 news release.
GFMA uses a lift-then-ablate technique to protect tissue and was performed safely in 20 patients. Mayo offers both procedures in a single 90-minute outpatient session for patients seeking nonsurgical, medication-free weight loss.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.